PSP Investments, a pension investment manager, led a $190m Series B funding round in Valo Health, a biotechnology firm. The round was joined by Flagship Pioneering, Invus, HBM Healthcare Investments, Atinum Investment and Mirae Asset Capital. "We have made tremendous progress in creating a fully integrated platform to accelerate the drug discovery and development process, making it far more efficient and less costly to provide life-saving treatments to patients. In less than two years, we have been able to build out our Opal computational platform and make significant progress on a number of programs, driving towards our ultimate goal of helping patients suffering from major diseases within our three therapeutic areas of focus, cancer, cardiovascular disease, and neurodegenerative disease. We are pleased to share some of the progress we have made in our path to new cancer therapeutics with the combined power of Opal, massive data, and a world-class team of experts," David Berry, Valo Founder & CEO.